期刊文献+

阿奇霉素与培氟沙星用于治疗急性肠炎患者的临床疗效比较 被引量:8

Comparison of Clinical Efficacies of Azithromycin and Pefloxacin in Treating Patients with Acute Enteritis
下载PDF
导出
摘要 目的:比较阿奇霉素与培氟沙星用于治疗急性肠炎患者的临床疗效。方法:选取2014年12月—2015年10月期间诊治的急性肠炎患者98例作研究对象,依据随机抽样法将其分为观察组(n=49)和对照组(n=49);两组患者均以常规内科治疗为基础,其中观察组患者均给予阿奇霉素治疗,对照组患者均给予培氟沙星治疗,比较两组患者职后的总有效率、临床症状缓解时间、医疗费用和不良反应的发生率。结果:观察组患者治疗后的总有效率为98.18%高于对照组为72.73%(P<0.05);不良反应的发生率为6.12%低于对照组为16.33%(P<0.05);同时观察组患者退热、出血症状消失时间均优于对照组(P<0.05);医疗费用也少于对照组(P<0.05)。结论:采用阿奇霉素治疗急性肠炎患者的临床疗效优于培氟沙星的疗效,且治疗的总有效率较高,各项临床症状缓解较快,用药安全性较高,医疗费用较低,是用于治疗急性肠炎患者理想的药物。 Objective: To compare the clinical efficacies of azithromycin and pefloxacin in treating patients with acute enteritis. Methods: 98 cases were selected in the patients with acute enteritis during December 2014 to October 2015 in the hospital, which was based on random sampling divided into observation group(n=49) and control group(n=49). Two groups of patients had conventional medical treatment which is based on observation group patients azithromycin treatment and control group pefloxacin therapy. Therapeutic effects were compared in patients in clinical remission time, medical costs and incidence of adverse reactions. Results: The total effective rate was 98.18% and the incidence of adverse reactions was6.12% in the control group the total effective rate was 72.73%, the incidence of adverse reactions was16.33%. At the same time, the observation group fever, bleeding and symptoms and signs disappeared which were shorter than the control group; the medical costs are less than that of the control group; in the treatment groups of patients, the incidence of adverse reactions was less and the difference was statistically significant(P <0.05) between the symptoms and signs of remission time and medical expenses of the group. Conclusion: The clinical efficacy of azithromycin in treating acute enteritis is significantly higher, total efficiency of the treatment higher, the clinical symptoms remission faster, higher patient medication safety and lower medical costs, so it can be used as an ideal antibiotic in acute enteritis.
作者 王克强
出处 《抗感染药学》 2016年第2期371-374,共4页 Anti-infection Pharmacy
关键词 阿奇霉素 急性肠炎 临床症状 缓解时间 azithromycin pefloxacin acute enteritis clinical symptoms remission time
  • 相关文献

参考文献8

二级参考文献59

  • 1李清平,朱红枫,郭渠莲,邹艳,陈书琴,唐章华,刘文君.痰热清注射液治疗小儿支气管肺炎临床评价[J].辽宁中医学院学报,2006,8(1):43-44. 被引量:31
  • 2Kolls JK,Linden A. Interleukin-17 family members and infla-mmation[J]. Immunity, 2004,21 : 467-476. 被引量:1
  • 3Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T(H) 17 lin-neage[J]. Nature, 2007, 441 (4) : 231-234. 被引量:1
  • 4Smiley KL,McNeal MM,Basu M,et al. Association of gamma interferon and interleukin-17 production in intestinal CD4+T ceils With protection against rotavirus shedding in mice intra- nasally immunized with VP6 and the adjuvant LT(RI92G)[J]. J Virol,2007,81 (8):3740-3748. 被引量:1
  • 5Megan EM,Patricia ZZ,Arlin BR,et al. Modulation of acute diarrheal illness by persistent bacterial infection[J]. Infection and Immunity,2008,76 ( 11 ) :4851-4858. 被引量:1
  • 6Stalhnach A,Giese T,Schmidt C,et al. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease[J]. Int J Colorectal Dis,2004, 19:308-315. 被引量:1
  • 7Fujino S,Andoh A,Bamba S,et al. Increased expression of interleukin 17 in inflammatory bowel disease[J]. Gut, 2003,52 : 65-70. 被引量:1
  • 8Mannon PJ,Fuss lJ,Mayer L,et al. Anti-interleukin-12 antibody for active Crohn's disease[J]. N Engl J Med,2004,351:2069-2079. 被引量:1
  • 9Yen D,Cheung J,Scheerens H,et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6[J]. J Clin Invest, 2006,116:1310-1316. 被引量:1
  • 10Ngeow YF, Suwanjutha S, Chantarojanasriri T, et al. An Asian study on the prevalence of a typical respiratory pathogens in community-acquired pneumonia [J]. Int J Infect Dis, 2005, 9: 144-153. 被引量:1

共引文献126

同被引文献52

引证文献8

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部